SUPERNUS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (SUPN)

Historical Holders from Q1 2014 to Q3 2025

Symbol
SUPN on Nasdaq
CUSIP
868459108
Type / Class
Equity / Common Stock, $0.001 par value per share
Shares outstanding
56M
All holders as of June 30, 2025
Q2 2025
Total 13F shares, excl. options
59.5M
Holdings value
$1.87B
% of all portfolios
0.004%
Grand Portfolio weight change
+0%
Number of holders
291
Number of buys
160
Number of sells
-114
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of SUPERNUS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (SUPN)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 14.7% $260M 8.2M BlackRock, Inc. Mar 31, 2025
ARMISTICE CAPITAL, LLC 9.28% +5.78% $165M $11.4M 5.2M +7.44% Armistice Capital, LLC Mar 31, 2025

Institutional Holders of SUPERNUS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (SUPN)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 1.07M $51.1M -$7.82M $47.79 39
2025 Q2 59.5M $1.87B +$9.63M $31.52 291
2025 Q1 59.1M $1.94B -$15.5M $32.75 288
2024 Q4 59.5M $2.15B -$16.2M $36.16 289
2024 Q3 59.7M $1.86B +$51.6M $31.18 268
2024 Q2 58.4M $1.56B +$37.8M $26.75 242
2024 Q1 56.5M $1.93B -$17.1M $34.11 247
2023 Q4 122K $3.54M +$2.19M $28.94 1
2023 Q3 56.7M $1.56B -$16.8M $27.57 234
2023 Q2 56.9M $1.71B +$26M $30.06 242
2023 Q1 55.3M $2B -$15.7M $36.23 253
2022 Q4 55.8M $1.99B +$9.2M $35.67 257
2022 Q3 53.2M $1.8B +$13.8M $33.85 232
2022 Q2 54.2M $1.57B +$43.4M $28.92 212
2022 Q1 53.5M $1.73B -$41.2M $32.32 218
2021 Q4 54.6M $1.59B +$20.5M $29.16 223
2021 Q3 54.4M $1.45B +$2.48M $26.67 217
2021 Q2 53.9M $1.66B +$28.5M $30.79 220
2021 Q1 53.1M $1.39B +$12.2M $26.18 218
2020 Q4 52.8M $1.33B +$29.3M $25.16 218
2020 Q3 50.4M $1.05B +$16M $20.84 201
2020 Q2 50.3M $1.19B +$47.1M $23.75 211
2020 Q1 47.5M $854M -$50.7M $17.99 191
2019 Q4 50.5M $1.2B +$9.11M $23.72 225
2019 Q3 50.2M $1.38B -$77.5M $27.48 232
2019 Q2 51.5M $1.7B +$15.9M $33.09 262
2019 Q1 53M $1.86B +$40M $35.04 279
2018 Q4 51.2M $1.7B -$14.3M $33.22 261
2018 Q3 51.5M $2.59B -$111M $50.35 279
2018 Q2 53.4M $3.19B +$187M $59.85 313
2018 Q1 51.2M $2.34B +$81.6M $45.80 305
2017 Q4 49.6M $1.98B -$48.6M $39.85 290
2017 Q3 50.8M $2.03B +$95.4M $40.00 271
2017 Q2 46.9M $2.02B +$105M $43.10 259
2017 Q1 46M $1.44B +$218M $31.30 240
2016 Q4 45.3M $1.14B -$18.5M $25.25 226
2016 Q3 46M $1.13B -$8.99M $24.73 216
2016 Q2 46M $938M +$63.3M $20.37 207
2016 Q1 44.6M $680M +$7.46M $15.25 205
2015 Q4 44.6M $600M -$43.2M $13.44 203
2015 Q3 46.8M $657M +$61.8M $14.03 179
2015 Q2 42.1M $715M +$79.1M $16.98 161
2015 Q1 40.4M $488M +$45M $12.09 115
2014 Q4 37.1M $308M +$10.7M $8.30 105
2014 Q3 35.5M $309M -$18M $8.69 92
2014 Q2 37M $404M +$41.9M $10.95 85
2014 Q1 33.4M $298M +$21.6M $8.94 81